Sio Capital Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Sio Capital Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-248,674	Closed	-$2.58M	–	59
2023 Q1	$2.58M	Hold	248,674	–	–	1.27%	17
2022 Q4	$2.48M	Hold	248,674	–	–	0.92%	22
2022 Q3	$2.49M	Hold	248,674	–	–	0.79%	20
2022 Q2	$2.49M	Hold	248,674	–	–	0.94%	29
2022 Q1	$2.45M	Hold	248,674	–	–	0.81%	31
2021 Q4	$2.48M	Hold	248,674	–	–	0.75%	36
2021 Q3	$2.47M	Sell	248,674 -51,326	-17%	-$513K	0.79%	37
2021 Q2	$3.06M	Hold	300,000	–	–	0.76%	43
2021 Q1	$3M	Hold	300,000	–	–	0.61%	52
2020 Q4	$3.2M	Buy	+300,000	New	+$3.05M	0.65%	53

Sio Capital Management's EUCRU Position: Q2 2023 in Review

Sio Capital Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2023, closing a stake of 248,674 shares — an estimated $2.58M sold.

Sio Capital Management first reported a position in EUCRU in Q4 2020 and held it in 10 quarters. The position peaked at $3.2M in Q4 2020. 0 funds tracked by Wall St. Rank hold EUCRU as of Q2 2023.

Sio Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2023 after selling out during the quarter.
Sio Capital Management sold 248,674 Eucrates Biomedical Acquisition Corp. Unit shares in Q2 2023, an estimated $2.58M.
Sio Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 10 quarters.
Sio Capital Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $3.2M in Q4 2020.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2023.

Based on Sio Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.